News

EditForce, Inc. (Headquarter: Fukuoka, President and CEO: Takashi Ono) announces that we have raised a total of 1.8 billion yen through a third-party allotment of new shares by March 22, 2023.

March 22, 2023

In this round of financing participated the Kyushu Regional Recovery Support Fund, which was established by the Regional Economy Revitalization Corporation of Japan ("REVIC") jointly with local financial institutions in the Kyushu region, in addition to the existing shareholders which are The University of Tokyo Edge Capital Partners Co., Ltd. ("UTEC"), Newton Biocapital and MP Healthcare Venture Management, Inc. which is the corporate venture capital of Mitsubishi Tanabe Pharma Corporation.

Takashi Ono, President and Representative Director, commented, "We have taken additional investment from existing shareholders as unchanged expectations for our technological potentialities and our further growth." He also stated, "The investment from the fund, which was established for economic recovery and revitalization in the Kyushu region, has made me feel strongly the responsibility and mission as a Fukuoka-based company."

We are a world-class startup company that possesses unique technology editing not only DNA but also RNA. We are currently promoting research and developments by applying this technology to drug discovery. We will continue our efforts to increase and promote our pipelines and to enhance and improve our platform technologies.

More Info:

https://www.editforce.co.jp/en...